Loading...
•
Sep 30, 2021
Tandem Diabetes Q3 2021 Earnings Report
Reported a strong third-quarter performance with increased pump shipments and sales, and improved gross and operating margins.
Key Takeaways
Tandem Diabetes Care announced strong Q3 2021 results with a 45% increase in sales to $179.6 million and a significant rise in worldwide pump shipments by 43%. The company also updated its full-year sales guidance to $685 million - $695 million.
Worldwide pump shipments increased 43 percent to 31,558 pumps.
Sales increased 45 percent to $179.6 million.
Gross margin improved to 54 percent of sales.
Operating margin improved to 4 percent of sales.
Tandem Diabetes
Tandem Diabetes
Tandem Diabetes Revenue by Geographic Location
Revenue by Geographic Location
United States Revenue
CapyFin.comOutside the United States Revenue
CapyFin.com Forward Guidance
Tandem Diabetes Care updated its financial guidance for the year ending December 31, 2021.
Positive Outlook
- Sales are estimated to be in the range of $685 million to $695 million, representing 37% to 39% annual sales growth compared to 2020.
- International sales are projected to be approximately $168 million to $173 million, indicating 102% to 108% annual sales growth compared to 2020.
- Gross margin is estimated to be approximately 54%.
- Adjusted EBITDA is estimated to be approximately 15% of sales.
- Non-cash charges included in cost of goods sold and operating expenses are estimated to be approximately $75 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income